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Available online 18 July 2013Abstract Genomic abnormalities may accumulate in human embryonic stem cells (hESCs) during in vitro maintenance.
Characterization of the mechanisms enabling survival and expansion of abnormal hESCs is important due to consequences of
genetic changes for the therapeutic utilization of stem cells. Furthermore, these cells provide an excellent model to study
transformation in vitro. We report here that the histone deacetylase proteins, HDAC1 and HDAC2, are increased in
karyotypically abnormal hESCs when compared to their normal counterparts. Importantly, similar to many cancer cell lines, we
found that HDAC inhibitors repress proliferation of the karyotypically abnormal hESCs, whereas normal cells are more resistant
to the treatment. The decreased proliferation correlates with downregulation of HDAC1 and HDAC2 proteins, induction of the
proliferation inhibitor, cyclin-dependent kinase inhibitor 1A (CDKN1A), and altered regulation of tumor suppressor protein
Retinoblastoma 1 (RB1). Through genome-wide transcriptome analysis we have identified genes with altered expression and
responsiveness to HDAC inhibition in abnormal cells. Most of these genes are linked to severe developmental and neurological
diseases and cancers. Our results highlight the importance of epigenetic mechanisms in the regulation of genomic stability of
hESCs, and provide valuable candidates for targeted and selective growth inhibition of karyotypically abnormal cells.
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http://dx.doi.org/10.1016/j.scr.2013.07.002Human embryonic stem cells (hESCs), with the capacity to give
rise to all the somatic tissues and germ cells, provide a valuable
tool for both basic research and future regenerative medicine
(Thomson et al., 1998). However, during in vitro maintenance
genomic abnormalities can accumulate in hESC lines. Interest-
ingly, the hotspots for the changes lie in chromosomes 1, 8, 12,
1023HDACs in Karyotypically Abnormal hESCs17, 20q10–11 and X, many of which are frequently affected in
germ cell tumors and other types of cancers (http://cgap.nci.
nih.gov/Chromosomes/RecurrentAberrations) (Baker et al.,
2007; Ben-David and Benvenisty, 2011; Draper et al., 2004;
International Stem Cell Initiative et al., 2011; Laurent et al.,
2011; Lund et al., 2012; Taapken et al., 2011). Human ESC lines
with genomic abnormalities display improved survival, prolif-
eration, cloning and self-renewal capacity and decreased
spontaneous differentiation making these demanding cells
much easier to maintain in culture (Andrews, 2006; Baker
et al., 2007; Draper et al., 2004; Enver et al., 2005; Herszfeld
et al., 2006; Maitra et al., 2005; Werbowetski-Ogilvie et al.,
2009). Accumulation of the genomic alterations in these
chromosomal hotspots is likely to give selective advantage
to the cells in culture and may indicate transformation of
the cells towards a malignant phenotype. Elucidation of the
mechanisms implicated in the culture adaptation process
may provide valuable information about the signaling
mechanisms important for the regulation of stem cell fate
and provide insights into the transformation of the stem
cells.
Previous study by Enver et al. (2005) on transcriptional
profiles of karyotypically normal and abnormal cells provided
data about the genes potentially important for the culture
adaptation of hESCs (Enver et al., 2005). To analyze further
the mechanisms regulating altered growth properties of
karyotypically abnormal cells, we have now re-examined
these data and identified the histone deacetylase HDAC1 as a
possible candidate implicated in the process. HDAC1 together
with HDAC2 forms a core component of several multiprotein
chromatin remodeling complexes, including Sin3, Nurd,
CoRest and NODE (Brunmeir et al., 2009). Of these particularly
Nurd and NODE complexes are known to be important in
regulation of pluripotency (Kaji et al., 2006, 2007; Liang et
al., 2008; Reynolds et al., 2012). Studies with mouse models
have shown that Hdac1, rather than Hdac2, is required for the
activity of chromatin modeling complexes, early embryonic
development and proliferation and differentiation capacities
of ESCs (Brunmeir et al., 2009; Dovey et al., 2010). Reduced
proliferation of HDAC1-knockout mESCs correlates with
decreased cyclin dependent kinase activity and elevated
p21 and p27 levels. Furthermore, HDAC1-knockout leads
to the decrease in overall histone deacetylase activity and
hyperacetylation of histone H3 and H4 subsets (Lagger et al.,
2002). HDAC1 does not bind to DNA; however, it can be
recruited to chromatin by several factors, such as SP1/SP3,
RB1 or p53 (Brunmeir et al., 2009). Through deacetylation of
histone proteins HDACs participate in controlling activity and
structural dynamics of chromatin. In addition to histone
proteins, HDAC1 is involved in regulation of stability of several
non-histone proteins, such as tumor suppressor protein p53
(Brunmeir et al., 2009; Luo et al., 2000). Despite the multiple
protein interactions, Hdac1 targets a specific set of genes in
mESCs (Zupkovitz et al., 2006) and localizes in promoters of
genes critical for self-renewal and pluripotency, including
Oct4, Nanog and Klf4 (Kidder and Palmer, 2012). In addition
to crucial function in the regulation of cellular differentiation,
Hdac1 has a key function in the regulation of cell cycle and
proliferation through negative regulation of CDKN1A (Zupkovitz
et al., 2006). Furthermore, HDAC1 interacts directly with RB1
to repress E2F targets regulating G1–S transition of the cell
cycle. This function mediated by HDAC1 and RB1 has beenthought to be the key element controlling cell proliferation and
differentiation and is target for transforming viruses (Brehm et
al., 1998; Magnaghi-Jaulin et al., 1998). Decrease in NuRD and
HDAC1 activity has been associated with aging (Pegoraro et al.,
2009; Willis-Martinez et al., 2010). On the other hand,
overexpression of HDACs has been linked to different cancers
(Brunmeir et al., 2009). Interestingly, HDAC inhibitors are
cytotoxic to several types of cancer cells inducing proliferation
block, apoptosis and differentiation, whereas normal cells are
more resistant. Thereby HDAC inhibitors are actively studied for
cancer treatment and vorinostat has been accepted for clinical
treatment of cutaneous T cell lymphoma (Dokmanovic et al.,
2007; Kelly and Marks, 2005; Coffey et al., 2001; Gottlicher et
al., 2001).
In this study we found that, similar to certain cancers,
karyotypically abnormal hESCs express increased levels of
epigenetic regulator proteins, HDAC1 and HDAC2, and are
more sensitive to HDAC inhibitors than their karyotypically
normal parent cells. Treatment of abnormal cells with HDAC
inhibitors leads to the decrease in proliferation which
correlates with dowregulation of HDAC1 and HDAC2 proteins
and induction of proliferation inhibitor CDKN1A (p21).
Furthermore, we show that HDAC1 binds to RB1 in hESCs
and inhibition of HDAC activity selectively induces phos-
phorylation of RB1 in abnormal hESCs but not in normal
hESCs. Finally, we show that the genes with altered
regulation in karyotypically abnormal hESCs and selective
responsiveness to the HDAC inhibition are associated with
severe developmental diseases, neurodegenerative dis-
eases, and cancers particularly those common in childhood.
Materials and methods
Cells and culture conditions
Human embryonic stem cell lines (Supplemental Table SI)
were cultured on mitotically inactivated (Mitomycin C,
Sigma) mouse embryonic fibroblasts in 80% knockout DMEM,
supplemented with 20% knockout serum, 4 ng/mL bFGF, 1%
nonessential amino acid solution, 1 mM L-glutamine (all from
Invitrogen) and 0.1 mM β-mercaptoethanol (Sigma-Aldrich)
(Thomson et al., 1998). Enzymatic passaging with Type IV
Collagenase (Life Technologies) and glass beads were carried
out for the cells when approximately 80% confluent. In some
of the experiments the cells were maintained on human
foreskin fibroblast feeders (CRL-2429, ATCC) as previously
described (Narva et al., 2012) and then maintained one
passage on Matrigel (BD Pharmingen) in mTeSR1 (STEMCELL
Technologies). The HDAC inhibition was performed with
chemical inhibitors by using indicated concentrations of
valproic acid (Cat No. 676380, La Jolla, CA) or CBHA (Cat No.
382148, Calbiochem).
High-content analysis
The high-content analysis was carried out as previously
described (Barbaric et al., 2010, 2011). Briefly, cells were
harvested with Accutase (Millipore) and 3000 karyotypically
abnormal cells per well or 5000 normal cells were plated per
well of a 96-well plate (M056-32EA, Sigma-Aldrich). The cells
were plated on mitotically inactivated mouse embryonic
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medium was supplemented with indicated concentrations of
two different HDAC inhibitors VPA or CBHA. For each
condition four to eight replicates were carried out. At the
indicated time points the cells were fixed with 4% parafor-
maldehyde for 20 min at room temperature, followed by
blocking with PBS supplemented with 2% FCS for 1 h at
+4 °C. The cells were stained with 10 μg/ml Hoechst 33342,
in house produced anti-TRA-1-60 (2 h at +4 °C) and 1:150
goat anti-mouse IgG + IgM (H + L) -FITC (Caltag, M30801).
After each step three washes with PBS supplemented with
2% FCS were carried out. Imaging of the stained cells was
carried out using the InCell Analyzer 1000 (GE Healthcare)
and images were analyzed using Developer Toolbox 1.7
software (GE Healthcare).
Co-immunoprecipitation
For the co-immunoprecipitation experiments the cells
were washed with ice cold PBS and were lyzed on ice
in 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1% Triton-X-100
supplemented with phosphatase and proteinase inhibitor
cocktail (Roche). The samples were sonicated and pre-
cleared with protein A agarose beads. The indicated anti-
bodies (1–5 μg) were added into the samples and the
samples were incubated in gentle rocking for 1 h. Protein A
beads were added into the sample suspension and the
samples were incubated overnight in gentle rotation. The
protein–antibody complexes bound to the beads were
collected by centrifugation (12,000 g, 20 s). The complexes
were washed 4 times for 20 min with ice cold buffer
containing 50 mM Tris–HCl (pH 7.5) and 120 mM NaCl.
Consequently, a wash with ice cold 10 mM Tris–HCl, pH 7.5
for 20 min was carried out. Finally, the complexes were
suspended in SDS buffer (62.5 mM Tris–HCl, pH 6.8, 2% SDS,
10% Glycerol, 50 mM DTT) and denaturated at 100 °C for
3 min. The beads were removed from the suspension by
centrifugation (12,000 g, 20 s). To examine the protein
interactions, the samples were further analyzed with
Western blot assay.
Western blot
For the Western blot the cells were lyzed in SDS buffer
(62.5 mM Tris–HCl, pH 6.8, 2% SDS, 1% glycerol, 50 mM fresh
DTT) and boiled for 5 min at 95–100 °C. The lysates were
sonicated and quantitated. Equal amounts of proteins were
separated based on mass in 5–10% acryl-amide gel electro-
phoresis and transferred into nitrocellulose (162-0112,
Bio-Rad) or PVDF (RPN303LFP, Amersham Biosciences)
membranes for immunoblotting. Membranes were blotted
with indicated antibodies and proteins were visualized
with Supersignal West Pico chemiluminescent substrate kit
(Pierce). See the Supplemental Table SVI for information on
the antibodies used in the experiments.
Flow cytometry
For the flow cytometry the cells were harvested with 0.05%
Trypsin + 0.4 mM EDTA and blocked with 1× PBS + 2% FCS
for 30–60 min. The flow cytometric analysis was carried outusing either living cells or cells fixed with 1–4% paraformal-
dehyde. For intracellular staining the cells were fixed with
ice cold 100% methanol for 10 min at −20 °C. The blocking
and staining of the cells was carried out in 1× PBS
supplemented with 2% FCS. The antibody incubations were
carried out for 30–60 min at +4 °C. Primary antibodies used
in the analysis (P3X63Ag8, SSEA1, SSEA3 or SSEA4) were
derived in house from hybridoma supernatants. See the
Supplemental Table SVI for detailed information on the
other antibodies used in the experiments. As a secondary
antibody anti-rabbit-Alexa647 (A-21245, Molecular Probes)
or anti-mouse-Alexa488 (1:500, A-11017, Molecular Probes)
or goat anti-mouse IgG + IgM (H + L) -FITC (1:150, M30801,
Caltag) was used. The samples were run with ADP CyAN
(Beckman Coulter) and data analysis was carried out with
Summit 4.0 Software (Beckman Coulter) or Cyflogic (CyFlo
Ltd).
Real-time RT-PCR
For the real-time RT-PCR the primers and probes (labeledwith
FAM and TAMRA) were designed at the Universal Probe Library
Assay Design Center (Roche). Total RNAs were extracted with
RNAeasy Mini Kit (Qiagen). cDNA was prepared from 0.5 to
1 μg of the DNAse I treated totRNA using Superscript II kit
(Invitrogen) and was used as a template for real-time RT-PCR
analysis (7900HT, Applied Biosystems). The fold differences
(FD = 2(IDCT1–DCT2I)) were calculated from the normalized CT
values (DCT = CTgene X − CThousekeeping gene) as indicated (Lund
et al., 2003). The oligos for real-time RT-PCR were designed
with Roche ProbeFinder Software and probes were ordered
from Roche Universal ProbeLibrary maintained at Finnish
Microarray and Sequencing Centre, Finland. The primers and
probe used in the measurements were the following: HDAC1
5′-cca agt acc aca gcg atg ac-3′ and 5′-tgg aca gtc ctc acc aac
g-3′, probe #58; LRP8 5′-tgt cca gat ggg agt gat ga-3′ and 5′-gtt
gtg cag aca ctc gtt cag-3′, probe #71; SPP1 5′-cgc aga cct gac
atc cag t-3′ and 5′-ggc tgt ccc aat cag aag g-3′, probe #61.
Transcriptome analysis
For re-analysis of the data by Enver et al. (2005), the original
CEL files were imported to R/Bioconductor (http://www.
bioconductor.org). The data was normalized with RMA
(Robust Multi-Array) normalization method and probe
sets with signal levels less than 100 in all the samples
were excluded. Significance analysis of microarrays (SAM),
siggenes, package was used to extract the genes showing
over 2-fold difference between karyotypically normal and
abnormal SSEA3+ cells with false discovery rate of 0 (Holger
Schwender, 2009, siggenes: Multiple testing using SAM and
Efron's empirical Bayes approaches, R package version
1.22.0). Ingenuity pathway analysis was run to identify
putative upstream regulators of the genes differentially
regulated in karyotypically normal and abnormal hESCs
(Ingenuity Systems).
For the genome-wide transcriptome analysis of karyotyp-
ically normal or abnormal cells grown in the presence or
absence of HDAC inhibitor (VPA), the RNAs were isolated
and DNAse I treated as described above. The quality was
controlled with Experion RNA Analysis kit (Bio-Rad, Hercules,
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Human HT-12 v3 Expression BeadChip. The samples for the
Illumina chips were processed from 200 ng of DNAse I treated
totRNA by the Finnish Microarray and Sequencing Centre,
Turku Centre for Biotechnology, Finland. The raw data was
processed with GeneSpring GX (Agilent). First the data was
quantile normalized and quality controlled. The differences
between four different conditions were identified through
pair-wise comparisons using appropriate T-test statistics.
Paired T-test statistics was used for the comparison of
untreated vs HDAC inhibitors treated and unpaired T-test
statistics was used to compare karyotypically normal cells to
abnormal cells. To reduce the number of false positives a
cut-off value of 2-fold was applied for the data filtering. In
addition to public databases (www.ncbi.nlm.nih.gov, http://
ist.medisapiens.com/, www.alzgene.org), Ingenuity Pathway
Analysis Tool (Ingenuity Systems) was utilized in the data
mining to seek information on the selected genes and
associated pathways.Induced shRNA knockdown of HDAC1For knockdown of HDAC1, a previously established system
(Zafarana et al., 2009) utilizing doxycyclin inducible
short hairpin RNA (shRNA) under control of Tet Repressor
protein responsive element was used. ShRNA sequences
targeting HDAC1 were cloned into the multiple cloning site
of pSuperior-GFP-Neo (Oligoengine) vector. The shRNA
sequences used in the experiments were from Biomers
(Germany): HDAC1 shRNA3: 5′-GAT CCC CCA GAA CAC GAA
TGA GTA CTT CAA GAG AGT ACT CAT TCG TGT TCT GGT TTT
TA-3′ and 5′-AGC TTA AAA ACC AGA ACA CGA ATG AGT ACT
CTC TTG AAG TAC TCA TTC GTG TTC TGG GG-3′; HDAC1
shRNA4: 5′-GAT CCC GGC TGG CAA AGG CAA GTA TTT CAA
GAG AAT ACT TGC CTT TGC CAG CCT TTT TA-3′ and 5′-AGC
TTA AAA AGG CTG GCA AAG GCA AGT ATT CTC TTG AAA TAC
TTG CCT TTG CCA GCC GG-3′. Briefly, the shRNA oligos were
annealed and ligated (T4 Ligase, New England Biolabs) into
the digested pSuperior vector purified from the 1% Agarose
gel (Qiaquick Gel Extraction kit, Qiagen). Competent
DH5alphaF cells were transformed with the ligated vectors
and screened for positive colonies from the LBA plates.
Transformants were identified with PCR directly from the
bacterial colonies using forward primer 5′-AGA ATT CGA
ACG CTG ACG TC-3′ and reverse primer 5′-GGA ACA AAA GCT
GGG TAC CG-3′. Plasmid DNAs were prepared and purified
with GenElute™ Endotoxin-free Plasmid Midiprep Kit (Sigma-
Aldrich). The positive clones were verified with restriction
enzyme analysis and sequencing. The NT2D1 cells carrying
pGAC-Rnls vector, for Tet Repressor protein expression, were
transfected with linearized plasmids at 50% confluency with
Lipofectamine 2000. Puromycin 1 μg/ml and G418 1 μg/ml
(both from Sigma) selection was added for selective expansion
of the clonal cell lines carrying both vectors pCAG-TetRnls and
pSuperior. Doxycyclin 1 ng/ml was added to induce the shRNA
expression. Knockdown of HDAC1 was analyzed at mRNA level
with TaqMan real-time RT-PCR and at protein level with
Western blot analysis. Three clones (shRNA3cl1, shRNA4cl2
and shRNA4cl4) were selected for further experiments, based
on efficient knockdown at mRNA and protein levels.Promoter analysis
Promoter analysis included DNA sequence scanning with
transcription factor motif sequences. Here, position weight
matrices (PWMs) of various transcription factors available in
TRANSFAC Professional database version 2009.3 (BIOBASE
GmbH) were used. The gene promoter sequences were
obtained from the UCSC upstream sequences (hg18, NCBI
Build 36.1). The promoters were scanned 1000 base pairs
upstream from the transcription start site. This was done
with the PWMs of all the 388 transcription factors that are
found in the database for Homo sapiens. For each PWM, a
MotifLocator score s, as implemented in Lahdesmaki et al.
(2008), for each base pair position in each promoter
sequence was calculated. A background distribution of
scores Sbg calculated from permuted promoter sequences
was constructed. Then each score s was compared to the
background distribution resulting in a p-value. The base pair
positions with a p-value b 0.001 were considered as binding
sites for the transcription factor at hand.
Results
HDAC1 and HDAC2 proteins are expressed at
increased levels in the karyotypically abnormal
hESCs
To elucidate the mechanisms that enable enhanced survival
and growth of karyotypically abnormal hESCs, transcriptome
data from the study of normal and adapted H7 hESCs by
Enver et al. (2005) was analyzed (Enver et al., 2005). From
this data set we identified histone deacetylase 1 (HDAC1) as
a possible factor involved in the process since it was among
the putative upstream regulators of the genes differentially
expressed between karyotypically normal and abnormal
hESCs (Ingenuity Pathway Analysis, Ingenuity Systems), and
the only putative upstream regulator showing over 2-fold
increase in gene expression in the abnormal hESC line
(Fig. 1A). Several of the known direct downstream targets
of HDAC1 or HDAC2 showed altered expression levels in
abnormal cells indicating altered activity of these factors
(Supplemental Fig. S1). Western blot analysis further
validated elevated levels of both HDAC1 and HDAC2 proteins
in three different hESC lines with genomic abnormalities
(Fig. 1B). The finding was further supported by flow
cytometric analysis, which demonstrated that the increased
levels of HDAC1 in abnormal cells were observed in both
SSEA3+ and negative populations (Fig. 1A) and in POU5F1
high and low populations (Fig. 1C), showing that the increase
is not caused by different proportion of spontaneously
differentiating cells present in the samples. Based on
karyotyping analysis (Supplemental Table SI) in H14 line
genomic loci for both HDAC1 (1p34) and HDAC2 (6q21), and
in Shef5 for HDAC2, have diploid dose of genes indicating
that other mechanisms than structural changes drive
enhanced expression of these proteins.
HDACs are known to negatively regulate acetylation level
of histone 3 (AcH3). Thereby we also examined the global
levels of this histone modification in normal and abnormal
cells. The Western blot analysis revealed increased rather
than decreased levels of the denaturated AcH3 protein in
Figure 1 Levels of HDAC1 and HDAC2 proteins are increased in the human embryonic stem cells with karyotypic abnormalities. In
panel A are the normalized mean gene expression intensities for HDAC1 gene, extracted from the raw Affymetrix oligonucleotide
array data from the study by Enver et al. (2005). The data shows gene expression of HDAC1 in the karyotypically normal vs abnormal
cell fractions sorted for SSEA3 marker. The standard deviations and T-test p-values are indicated in the figure. In panel B are the
Western blot data on HDAC1, HDAC2, AcH3, stem cell marker POU5F1 and housekeeping gene beta-actin (ACTB) in three different
hESC lines (H7, H14 and Shef5) with karyotypically normal (N) and abnormal (AB) counterparts. In panel C is the double staining for
HDAC1 and POU5F1 levels as measured with flow cytometric analysis in karyotypically normal (N) or abnormal (AB) H7 hESC lines and
in panel D are the levels of AcH3 in normal and abnormal cells as measured with flow cytometric analysis. The median intensity levels
are shown in the figure for the secondary antibody controls (dashed lines) and for the normal (N) and abnormal (AB) cells stained for
AcH3.
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chromatin present in these cells (Fig. 1B). On the opposite,
flow cytometric analysis indicated a slight decrease in the
levels of native AcH3 in abnormal cells, which may indicate
altered function of HDACs or decreased accessibility of the
antibody to chromatin due to more compact chromatin
structure (Fig. 1D).HDAC inhibitors prevent proliferation of hESCs with
abnormal karyotype
To assess whether inhibition of HDAC activity has an
effect on the growth of karyotypically abnormal hESCs,
the cells were cultured under increasing concentrations
of two different HDAC inhibitors, valproic acid (VPA) and m-
carboxycinnamic acid bis-hydroxamide (CBHA). High content
analysis of the cells stained with Hoechst 33342 and stem
cell marker TRA-1–60 revealed that treatment with either
of these inhibitors leads to a decrease in the number of
colonies and TRA-1–60+ cells within the colonies in a dose
dependent manner (Fig. 2). With VPA the effect on cellnumbers was observed already after one day of treatment
with the concentration ≥0.75 mM (p ≤ 0.05); however,
higher concentrations were more efficient in maintaining
the growth inhibition throughout the experiment. With CBHA
the lowest effective concentration was 0.5 μM (p ≤ 0.001)
observed after 3 days of treatment. The dose dependent
growth inhibition by HDAC inhibitors and morphology of the
treated cells indicated that the effect was rather due to
block in the proliferation rather that induction of apoptosis,
autophagy or necrosis.
To study whether HDAC inhibitors affect growth of cells
with normal karyotype, we grew H7 cells with normal or
abnormal karyotype in parallel under increasing concentra-
tions of VPA or CBHA. The results show that whereas HDAC
inhibitors strongly prevented high expansion of the karyo-
typically abnormal hESCs, the cells with normal karyotype
grew better under similar conditions. The growth of the
normal cells was not decreased by VPA treatment, whereas
the growth of the abnormal cells was affected with
concentration of ≥1 mM of VPA. The calculated average
half maximal effecting concentration (EC50) was 1.12 mM of
VPA for abnormal cells (Figs. 3A–C). The karyotypically
Figure 2 HDAC inhibitors prevent proliferation of human embryonic stem cells with abnormal karyotype. Growth curve data for the
abnormal hESCs (H7) grown under increasing concentrations of HDAC inhibitors valproic acid (VPA), or m-carboxycinnamic acid
bis-hydroxamide (CBHA) for 4 days. For the assay the cells were harvested with accutase and plated on inactivated MEFs into 96-well
plates. On the following day the cultures were supplemented with increasing concentrations of VPA or CBHA, as indicated. For
monitoring the growth under different conditions the cells were stained with nuclear stain (Hoechst) and stem cell marker TRA-1-60
and high content analysis of the cell proliferation was carried out (IN Cell Analyzer, GE Healthcare Life Sciences) at indicated time
points. The growth curves show the average numbers of TRA-1-60+ cells per colony for the cells grown under VPA (A), or CBHA (B). In
panel C is the total number of colonies on day 4 under increasing concentration of VPA, and in panel D for CBHA. The error bars are the
standard deviations and asterisk indicates statistical significance with the unpaired T-test p-value * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001,
shown only for day 4.
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normal cells. However, the growth of normal cells was also
affected by CBHA, although not as strongly as the growth of
abnormal cells. With CBHA EC50 was 0.60 μM for abnormal
cells and 1.41 μM for normal cells (Fig. 3D). Thus, VPA
seems to be more promising for the selected growth
inhibition of abnormal cells, as it is better tolerated by the
karyotypically normal cells. Growth inhibition of abnormal
cells in response to VPA correlated with downregulation of
HDAC1 protein and induction of CDKN1A (p21), a known target
of HDAC1 and inducer of cell cycle arrest (Fig. 3E). Induction of
CDKN1A was not detected in normal cells or in abnormal cells
in response to CBHA (data not shown). Levels of HDAC1 were
not repressed in karyotypically normal hESCs (Fig. 3G). As
expected, levels of AcH3 were increased in abnormal cells in
response to VPA (Figs. 3E–F) as well as CBHA (Supplemental
Fig. S2A). In conclusion, similar to the cancer cells and normalcells found in somatic tissues, abnormal hESC is more sensitive
to HDAC inhibitors than normal cells.
HDAC inhibition does not induce differentiation of
the hESCs
As HDAC inhibition has been reported to induce differenti-
ation of certain cancer cell types, the levels of stem cell
markers, SSEA3 and SSEA4, and the differentiation marker
SSEA1 were studied after exposure of hESCs to HDAC
inhibitors. Analysis of the karyotypically abnormal hESCs
grown under effective VPA concentration was challenging
due to decreased growth and survival of the cells and in
several experiments not enough cells could be harvested for
flow cytometric analysis. However, based on the successful
experiments HDAC inhibition does not induce differentiation
of either karyotypically normal or abnormal cells (Fig. 4A).
Figure 3 Normal human embryonic stem cells are more resistant to HDAC inhibition. Karyotypically normal (N) or abnormal (AB)
hESCs (H7) were plated on mitotically inactive mouse embryonic fibroblast feeders. One day after plating the cultures were
supplemented with HDAC inhibitor VPA as indicated. In panel A is the cell morphology after 3 days under increasing concentrations of
VPA. In panel B is the proportional number of cells grown under VPA as compared to the untreated control. For growth curve assay the
cells were dissociated into single cells with accutase and were plated in equal numbers on mouse feeders. One day after plating the
cultures were supplemented with VPA or CBHA. For monitoring the growth under different conditions the cells were stained with
nuclear stain (Hoechst) and high content analysis of the cell proliferation was carried out. The percentage of average cell numbers as
compared to untreated control cells, after 5 days of VPA treatment is shown in panel C, and that of CBHA in panel D. The error bars
indicate the standard deviations between four replicates. The asterisk indicates statistical significance with the unpaired T-test
p-value * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001. In panel E are the levels of HDAC1, HDAC2, acetylated H3 protein (AcH3), CDKN1A (p21) and
housekeeping gene ACTB proteins under increasing concentrations of VPA in abnormal (H7). In Fig. 1F is the flow cytometric
measurement of the AcH3 levels in abnormal H7 cells grown in the absence or presence of 3 mM VPA for 3 days. The mean intensity
values for the samples are indicated in the figure. See Supplemental Fig. S2 for CBHA treatment. In panel G is the Western blot data of
HDAC1 and housekeeping gene GAPDH in the karyotypically normal HS360 and H7 hESC lines grown under valproic acid treatment as
indicated in the figure for 3 days.
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under phase contrast microscope (Fig. 3A). Also no clear and
consistent changes in POU5F1 protein levels were observed
in response to VPA, although in some of the cultures slightdecrease with high concentrations of inhibitor was observed
(Fig. 4B). Similar observations were made with CBHA
(Supplemental Fig. S3). In conclusion, HDAC inhibition does
not induce differentiation of hESCs.
Figure 4 HDAC inhibition does not induce differentiation of human embryonic stem cells. The karyotypically normal (N) or
abnormal (AB) H7 cells were grown with or without HDAC inhibitor (valproic acid) for 3 days as indicated in the figures. The levels of
(A) SSEA1, SSEA3 or SSEA4 were measured with flow cytometric analysis and (B) POU5F1 and housekeeping gene GAPDH with Western
blot analysis to determine the differentiation status of the cell. See also Fig. S3 for CBHA treatment.
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karyotypically abnormal hESCs
Previous studies have indicated a key function for the RB–
HDAC1 complex in the regulation of cell proliferation and
differentiation through repression of E2F target genes
(Brehm et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et
al., 1998). Thus we studied how RB1 is regulated in these
conditions. Enhanced levels of RB1 were repeatedly, though
not exclusively observed in the abnormal hESCs when
compared to the normal cells, particularly in H7 line
(Figs. 5A–B). The variation in the levels may be partly
explained by the differentiation status of the cells, as in
karyotypically normal cells POU5F1 low and negative cells
clustered into several different populations with variable
levels of RB1 proteins. In contrast, abnormal cells had morehomogenous cell population positive for both POU5F1 and
RB1 (Fig. 5C). Interestingly, although no clear differences in
the phosphorylation status of RB1 protein were observed in
the normal and abnormal cells, our data shows that in
response to HDAC inhibition RB1 became differentially
modified in abnormal cells, but not in normal cells
(Fig. 5D). We then next examined whether HDAC1 binds to
RB1 in hESCs. As HDAC1/2 has been reported to form the
NODE complex with Pou5F1 in mouse ESCs, we also included
this protein in the analysis. Co-immunoprecipitation exper-
iments revealed interaction of HDAC1 with RB1 in abnormal
hESCs (Fig. 5E). Interaction of HDAC1 and RB1 in normal cells
was also observed in one of the replicates; however, it could not
be confirmed as level of HDAC1 is often weak in normal cells.
Similar observations were made for HDAC2. POU5F1 clearly
co-precipitated with RB1 in both normal and abnormal cells.
Figure 5 Altered regulation and binding of RB1 with HDAC1 in karyotypically abnormal human embryonic stem cells. Expression
level of RB1 protein was measured in karyotypically normal (N) or abnormal (AB) hESCs as indicated with Western blot analysis (A),
flow cytometric analysis with single staining (B) and co-staining with stem cell marker POU5F1. In the panel D is the Western blot data
for RB1 protein levels in the karyotypically normal or abnormal cells grown in the absence or presence of valproic acid (VPA) for
3 days. In panel E binding of RB1 with HDAC1, and a panel of indicated proteins, were examined with antibody based
co-immunoprecipitation in karyotypically normal (N) or abnormal (A) hESCs. In the figure is the representative Western blot data from
several co-immunoprecipitation experiments with a panel of antibody controls originated in r = rabbit or m = mouse hosts.
1030 R.J. Lund et al.In conclusion, these data indicate that HDACs enable survival
and regulate the altered growth properties of abnormal hESCs
possibly in a RB1 dependent manner. HDACs bind to RB1 andHDAC inhibition selectively affects phosphorylation status of
RB1 in karyotypically abnormal hESCs and induces an antagonist
of RB1, CDKN1A protein enabling proliferation block.
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altered regulation and sensitivity to HDAC inhibition
in karyotypically abnormal hESCsTo examine further the mechanisms of HDAC mediated
signaling and to clarify how HDACs support survival and
growth of the abnormal cells, whole genome transcriptome
analysis was carried out on the normal and abnormal cells
cultured in the presence or absence of HDAC inhibitor. In
concordance with the previous data by Enver et al. (2005),
differential expression of HDAC1 (2.28-fold, p b 0.001)
was observed in untreated karyotypically normal vs
abnormal hESCs, whereas no major differences were
observed in the mRNA levels of stem cell markers
POU5F1, NANOG and SOX2 (Supplemental Table SII).
Transcriptional profiling revealed that in karyotypically
normal hESCs 45 entities (probes), corresponding to 44
genes, were responding to HDAC inhibition with the chosen
filtering criteria (Fig. 6A, Supplemental Table SIII). Of
these genes, 41 were upregulated and only 3 were
downregulated indicating that the HDAC mediated gene
regulation in normal hESCs was mostly repressive rather
than inductive. Notably, nearly all of the genes regulated
by HDAC inhibition in normal cells (n = 41) showed
consistent changes also in the karyotypically abnormal
hESCs, although for many genes the changes in abnormal
cells were not as strong as in normal cells.
Interestingly, in the karyotypically abnormal hESCs, there
was a significantly higher number of entities (n = 212,
corresponding to 203 genes) responding to HDAC inhibition
with the selected filtering criteria (Supplemental Table SIV).
This was in line with the observations that abnormal cells are
more sensitive to HDAC inhibition than normal cells. HDAC1
or HDAC2 transcripts did not change in response to HDAC
inhibition in either normal or abnormal cells indicating that
the inhibition does not affect the transcription of these
genes. Pathway analysis of the genes regulated by HDAC
inhibitor in abnormal cells links these factors with cancer (69
genes) and functional networks regulating cellular growth,
proliferation, development and death. Among the genes
regulated in response to HDAC inhibition were several
previously known mouse Hdac1 target genes, such as H19
(imprinted endoderm marker), STMN2 (neuronal growth
associated), ACTG2, SOX12, GBX2, TUBB3 (ectoderm mark-
er) and FHL1 (Zupkovitz et al., 2006). All of these were
induced in response to VPA treatment, except ACTG2 which
was repressed. Strikingly, a stem cell marker DPPA5 was
highly induced (average 24-fold increase) in abnormal cells
in response to HDAC inhibition. Although this gene is known
to be highly expressed by ESCs, embryonic stem cells or
mouse deficient for Dppa5 are perfectly normal (Amano
et al., 2006). Taken together, in accord with the growth
curve data, karyotypically abnormal hESCs aremore sensitive to
HDAC inhibition having increased number of genes responding
to the treatment. The genes regulated in response to HDAC
inhibition include both stem cell and differentiation markers,
although, no clear signs of differentiation were observed in
response to the treatment.
To understand how HDAC inhibition selectively affects
the growth and survival of the abnormal cells, the genes
responding to HDAC inhibition in the abnormal cells anddifferentially expressed by the normal and abnormal cells
were extracted revealing 31 entities for 29 different genes.
Among these genes, two patterns of expression profiles were
observed. In the first profile pattern, the differences in gene
expression between normal and abnormal cells were
potentiated by the HDAC inhibition in both conditions
thereby not explaining the selective growth inhibition of
abnormal cells (Fig. 6B). More interestingly, in the second
profile pattern the genes with altered expression in the
abnormal cells were selectively affected by HDAC inhibition,
which reversed expression of these genes back to the levels
observed in karyotypically normal cells (Fig. 6C). Among
these the genes ARHGEF6, ATP6V1B1, MBD3L3, DAZL and
LRP8 were expressed at increased levels in abnormal cells
and were downregulated in response to HDAC inhibition. The
genes including TNFRSF19, NLRP1, PMP22, ID2, ARID5B,
PROM1, NEFM, EPHA4 and SPP1 showed decreased expres-
sion in the abnormal cells and were upregulated in response
to HDAC inhibition. Functional analysis of these genes, with
altered expression and selective sensitivity to HDAC inhibi-
tion in abnormal cells, revealed link to germ cell differen-
tiation, neuronal development and regulation of apoptosis.
Importantly, nearly all of the genes are associated with
severe developmental and neuronal diseases, in particular
neurodegenerative diseases, such as Alzheimer's disease.
Furthermore, nearly all of the genes were linked to cancers,
including leukemia, neuroblastoma, glioma and sarcomas,
which are cancer types particularly common in childhood
(www.cancer.gov) (Table 1).
At least 6 of these 14 genes are known to be aberrantly
regulated in leukemias, particularly in acute lymphoblastic
leukemia (ALL). Thus, it was studied whether HDAC
inhibition could also prevent proliferation of T-ALL cells
(CCRF-CEM line). Indeed, similar to the abnormal hESCs,
proliferation of these cells was decreased when grown in the
presence of HDAC inhibitor (Supplemental Fig. S4A). More-
over, RT-PCR analysis showed that levels of SPP1 were
induced whereas LRP8 was repressed in response to HDAC
inhibition indicating that similar mechanisms are supporting
growth of both abnormal hESCs and T-ALL cells derived from
somatic tissue (Supplemental Fig. S4B).Proliferation of NT2D1 cells and transcription of
SPP1 and LRP8 are dependent of HDAC1In order to examine whether the inhibition of growth and
transcriptional effects were HDAC1 dependent, we used
NT2D1 cell line and created clones expressing doxycyclin
inducible shRNAs targeting HDAC1. Three clones with
efficient knockdown of HDAC1 in response to doxycyclin
treatment were selected for the experiments (Supplemental
Fig. S5A–B). As was observed with the hESC lines, HDAC1
knockdown did not induce differentiation of NT2D1 cells
(data not shown). However, induction of HDAC1 knockdown
in NT2D1 cells induced similar enhancement of SPP1 gene
and repression of LRP8 gene within 2 days, as was observed
in response to VPA treatment in abnormal hESC cells or
CCRF-CEM cell line (Supplemental Fig. S5C–D). Also the
growth of the NT2D1 cells was reduced but not fully blocked
by HDAC1 knockdown (Supplemental Fig. S5E).
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genes
The HDAC inhibitor responsive genes with altered regulation
in transformed cells together with their upstream regulators
provide valuable candidates for targeted inhibition of
abnormal growth. To obtain further information of thepotential regulators of these selected genes of interest
(Table 1), the proximal promoters were studied up to
1000 bp upstream of the transcription starting site. Putative
transcription factor binding sites, present in the promoters
of all 14 genes, were extracted and consisted altogether of
28 factors (Supplemental Table SV). Functional analysis of
the putative upstream regulators revealed that 27 of 28
factors, excluding AR, are linked to development of the
hematological system (Ingenuity Pathway Analysis, Ingenuity
Systems). Among these 28 factors, binding sites for SP1
protein (gene at 12q13.1), were the most prominent in the
promoters of the genes listed in Table 1. SP1 is known to
mediate attachment of HDAC1 into the genomic DNA
(Brunmeir et al., 2009). Database search revealed that SP1
protein is known to directly interact with all HDAC1, HDAC2,
RB1, POU5F1 and NANOG proteins (Ingenuity Pathway
Analysis). Thus, SP1 probably acts as a common mediator
of DNA binding to regulate activity and expression of shared
target genes of these proteins. Binding sites for POU5F1
were found in the promoters of all of the genes except LRP8,
TNFRSF19, EPHA4 and NEFM. Among the putative upstream
regulators were also proteins, TP53, YY1 and E2F1, with well
known roles in transformation and oncogenesis. Similar to
RB1, these proteins are known to be bound and deacetylated
by HDACs (Brunmeir et al., 2009). These data together with
the co-immunoprecipitation results suggest that HDACs
co-operate with RB1, POU5F1 and possibly with NANOG and
SP1 to regulate expression of these 14 HDAC inhibitor
responsive genes differentially expressed in karyotypically
normal and abnormal hESCs. Further studies are needed to
clarify how these proteins target chromatin and regulate
genes in normal and transformed cells.Discussion
Characterization of the karyotypically abnormal cells and
culture adaptation process is important for stem cell biology
and can provide valuable insights into the mechanisms
regulating transformation of cells towards malignant fate.Figure 6 Transcriptome analysis reveals the genes with
altered regulation and sensitivity to HDAC inhibition in karyo-
typically abnormal hESCs (see also Supplemental Tables SII–IV).
Whole genome transcriptome analysis was carried out on the
karyotypically normal (N) or abnormal (AB) H7 hESCs grown in
the presence or absence of HDAC inhibitor (HDACi: valproic
acid: 0, 1.5 mM) for 3 days. T-test statistics and fold change
cut-off value 2 were applied to extract the genes differentially
expressed between indicated sample groups. In panel A is a
Venn diagram showing the numbers of genes differentially
regulated in the indicated conditions. In panels B–C are the
expression profiles of the 31 genes differentially expressed in
normal and abnormal cells and affected by HDAC inhibition. In
panel B are the genes where the differential expression
between normal and abnormal cells was potentiated by HDAC
inhibition. In panel C are the genes of interest with altered
expression in abnormal cells and differential responsiveness to
HDAC inhibition when compared to karyotypically normal cells.
See also Supplemental Figs. S4 and S5 for HDAC inhibitor and HDAC1
mediated proliferation effect and transcriptional regulation of SPP1
and LRP8 genes in cancer cells.
Table 1 Function and disease associations of the HDAC inhibition sensitive genes with altered regulation in karyotypically
abnormal hESCs.
Symbol Full name Genomic
locus











2p13.1 Acidification, distal renal tubular
acidosis, hearing loss, sperm
maturation.
Breast, ovarian and peritoneal
cancers, other urogenital tumors
DAZL Deleted in
azoospermia-like
3p24.3 Translation, differentiation, severe










1p34 Cell death, Alzheimer's disease risk,
increased fetal growth.
ALL, skin, squamous cell carcinoma,





13q12 Apoptosis, biomarker for melanoma. Head and neck, liver, prostate,
uterine, other neuroectodermal
cancers, sarcoma, melanoma, skin,
squamous cell carcinoma, lung
carcinoid tumors




2p25 Apoptosis, malignancy, hypoxia,
inhibitor of differentiation.
ALL, glioma
NLRP1 NLR family, pyrin
domain containing 1
17p13.2 Apoptosis, vitiligo, autoimmune
diseases.













17p12-p11.2 Differentiation, proliferation, Charcot–
Marie–Tooth disease IA, Dejerine–Sottas
synd., hereditary neuropathy.
Glioma, sarcoma, testicular,
neuroblastoma, breast or pancreatic
cancers, melanoma
PROM1 Prominin 1 (CD133) 4p15.32 Hematopoietic stem cell antigen,
inhibitor of differentiation, retinitis
pigmentosa, Stargardt disease.
Sarcoma, colorectal, pancreatic,




8p21 Cytoskeleton, biomarker of neuronal
damage, schizophrenia.
Sarcoma, lung tumor, glioma,
neuroblastoma, head and neck, other
neuroectodermal, adrenal gland,
kidney, testicular or cervical
cancers, other urogenital tumors
EPHA4 EPH receptor A4 2q36.1 Survival, differentiation, neuronal
development, potentiates FGFR
signaling, Parkinson's, Alzheimer's and
Huntington's diseases.
Sarcoma, mesothelioma, melanoma,






4q21–q25 Proliferation, growth, anti-apoptotic,
inflammatory diseases, Parkinson's
disease, cancers.
Glioma, lung cancer, mesothelioma,
kidney cancer
1033HDACs in Karyotypically Abnormal hESCsIn this study we show that the levels of the epigenetic
regulators, HDAC1 and HDAC2 proteins, are increased in the
hESCs with genomic abnormalities. Importantly, we furtherdemonstrate that, similar to many cancer cell lines, HDAC
inhibitors repress proliferation of the karyotypically abnor-
mal hESCs, whereas normal cells are more resistant to the
1034 R.J. Lund et al.treatment. The reduced growth of abnormal hESCs in
response to HDAC inhibition correlated with increased levels
of AcH3 and CDKN1A and with altered regulation of RB1.
Interestingly, levels of both HDAC1 and HDAC2 proteins were
decreased in response to both VPA and CBHA treatments.
Valproic acid prevents catalytic activity of type I HDACs;
however, it does not necessarily induce degradation of the
target protein. Previously, in HEK293T human embryonic
kidney carcinoma cells and mouse F9 teratocarcinoma cells
VPA has been shown to specifically induce proteosomal
degradation of HDAC2, whereas HDAC1 levels were not
reduced (Gottlicher et al., 2001; Kramer et al., 2003). Taken
together, our findings suggest that HDACs are implicated in
the stem cell transformation and support self-renewal of
abnormal cells.
Although HDAC1 has been reported to be crucial for the
growth and normal development of the mouse embryos
(Brunmeir et al., 2009), our observation is that HDAC
depletion with valproic acid, at least up to the concentra-
tion of 1.5 mM, does not have any major impact on the
self-renewal and proliferation of the karyotypically normal
hESCs. This is consistent with the findings in a recent study
where HDAC1 deficiency did not affect proliferation of the
mouse embryonic stem cells, but rather was required for the
efficient differentiation of the cells (Dovey et al., 2010).
HDACs are indeed known to be key factors in directing
differentiation of the stem cells to certain lineages, such as
neuronal and hematopoietic lineages (Brunmeir et al., 2009;
Cunliffe and Casaccia-Bonnefil, 2006; Dovey et al., 2010;
Humphrey et al., 2008; Wada et al., 2009), probably
indirectly by targeting non-histone proteins and directly
through epigenetic modifications of the regulatory areas of
genes important for differentiation and development. While
our study was in progress another study by Ware et al. (2009)
reported that HDAC inhibitors support self-renewal of both
human and mouse ESCs in the absence of FGF2 or LIF,
respectively. In contrast, they also reported that karyotypic
abnormalities were observed at equal frequencies under
HDAC inhibitor when using butyrate, vorinostat, trichostatin
or butyryl than in the absence of these compounds.
However, the karyotypic results for cells cultured under
valproic acid were not reported and importantly it did not
become clear whether changing the concentrations of HDAC
inhibitors under well controlled setup would reveal a
concentration for selective suppression of abnormal cell
growth. Ware et al. used only 0.5 mM valproic acid, which in
our hands is too low concentration to prevent growth of
abnormal cells.
Our data shows that HDACs communicate with well known
proteins implicated in oncogenic processes, such as RB1 and
POU5F1 in hESCs. Possibly through co-operation with RB1
and other factors, HDACs modulate activity of genes
implicated in development, cell growth and transformation
enabling survival of cells with genomic abnormalities.
According to our results HDAC inhibition is cytotoxic to
abnormal hESCs, whereas normal cells are more resistant to
the treatment. This selective sensitivity of the transformed
cells is similar to the cells in somatic tissues as reported by
several preclinical studies for a wide range of different
cancer types. HDAC inhibitor vorinostat has been approved
for clinical use in the treatment of cutaneous T cell
lymphoma and several others are currently under evaluation(Chateauvieux et al., 2010). We have also here confirmed
the growth inhibitory effect of HDAC inhibition on human
acute lymphocytic leukemia cell line (CCRF-CEM) and
embryonal carcinoma cells (NT2D1) derived from germ cell
tumor. The mechanism behind the antitumor effect of HDAC
inhibition has remained unclear.
A whole genome transcriptome analysis was carried out to
clarify the mechanisms of the cell type specific cytotoxicity of
HDAC inhibition on the abnormal cells. The transcriptome
analysis revealed the HDAC inhibitor responsive genes in the
normal and abnormal cells. The genes with altered levels in
abnormal hESCs and reciprocal regulation in response to HDAC
inhibition were identified as putative factors explaining
selective sensitivity of abnormal hESCs to HDAC inhibition.
Previous studies with mouse cells have shown that many of
these genes are direct targets of Hdac1, including Tnfrsf19,
Id2, Arid5B and Epha4 in mouse ESCs and in Lrp8 and Pmp22 in
mouse trophoblast cells (Kidder and Palmer, 2012) and SPP1 in
human fibroblasts (Pazolli et al., 2012). We have further
validated that LRP8 and SPP1 are regulated in HDAC1
dependent manner in human embryonal carcinoma cells
(NT2D1) correlating with the reduced growth of the cells
after HDAC1 knockdown. The genes with altered expression
and selective sensitivity to HDAC inhibition in abnormal cells
are linked to development and age associated to severe
developmental and neurological diseases and cancers, such as
Alzheimer's disease, Parkinson's disease, gliomas or leukemias.
This indicates that the genes showing altered expression and
selective sensitivity in HDAC inhibition in abnormal cells are
important for the normal cellular differentiation, development
and aging. On the other hand these genes link functionally to
neuronal and hematological development and seem to be
vulnerable to culture induced changes. Consistently, including
HDAC1, most of the putative upstream regulators of these
genes have previously known function in hematological
development. In addition, many of them, such as TP53 and
YY1, link to transformation and oncogenesis. These observa-
tions may partly explain why HDAC inhibitors are promising or
effective in the treatment in leukemias. These candidate
genes with altered regulation in abnormal cells and their
upstream regulators are likely to be important for the
improved survival and proliferation of the abnormal hESCs
and are highly valuable as potential targets for prevention of
abnormal or malignant growth.
Whether the activity of HDACs is increased before or
after genomic alterations occur in stem cells remains to be
elucidated. Interestingly, a recent study describes a key
function of HDAC1 and HDAC2 in DNA damage response
to promote DNA nonhomologous end-joining. Moreover, hyper-
sensitization of HDAC1/2 deficient cells to DNA damage
inducing agents was demonstrated (Miller et al., 2010).
Thus, it is possible that accumulation of abnormalities in
the HDAC1/2 proteins themselves may pronounce the cells
to DNA damage and genetic instability. This is further
supported by a recent study showing that HDAC1 and Nurd
complex are the key modulators of aging related chromatin
defects in primary fibroblasts and activity of HDAC1 is
decreased during aging (Pegoraro et al., 2009). Thus,
defective function of HDACs and accumulation of genomic
abnormalities in the stem cells during extended culture may
mimic senescence of the cells and in particular long-lived stem
cells residing in aging somatic tissues. Similar to ESCs, changes
1035HDACs in Karyotypically Abnormal hESCsoccurring in the chromatin of long-lived somatic stem cells are
likely to affect the growth, differentiation and regenerative
potential of these cells exposing the tissues to malignant
growth and degenerative diseases. Future studies determining
the importance of HDAC mediated protein complexes in
the maintenance of somatic stem cells in aging tissues and
their contribution to malignant and age related degenerative
diseases will be of great interest.
Supplementary data to this article can be found online at
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